Avita reports data from pivotal trial of ReCell for second-degree burns

Avita Medical Ltd. (ASX:AVH; OTCQX:AVMXY) reported data from a pivotal trial evaluating ReCell to treat deep partial-thickness (second-degree) burns. ReCell is a point-of-care autologous cell harvesting device that creates a regenerative epithelial suspension (RES) to regenerate skin.

Avita said the patient donor skin requirement for harvest was 97.5% lower with ReCell compared with standard meshed autograft (p<0.001). ReCell also significantly reduced donor-site pain and improved patient satisfaction with donor-site appearance, scarring results and healing vs. standard meshed autograft...